200619-13-2

Molecular Formula	C22H20N2O6
Molar Mass	408.4
Solubility	DMSO : 50 mg/mL (122.43 mM; Need ultrasonic)
Storage Condition	2-8℃
In vitro study	DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype.
In vivo study	In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies.

Last Update：2024-01-02 23:10:35

biological activity	DRF-1042 is an orally active camptothecin analog, it has the effect of inhibiting DNA topoisomerase I (DNA topoisomerase I). DRF-1042 showed good anticancer activity against a group of human cancer cell lines, including multidrug resistance (MDR) phenotypes.
Target	DNA topoisomerase I

Last Update：2024-04-09 19:05:17

Product Name: DRF-1042 Visit Supplier Webpage Request for quotation
CAS: 200619-13-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Product Name: DRF-1042 Visit Supplier Webpage Request for quotation
CAS: 200619-13-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

200619-13-2

200619-13-2 Request for Quotation